PE and M&A Hit 85 Deals in Two Weeks — Technology and Financial Services Lead the Surge

Eighty-five M&A deals closed across global markets in the past two weeks, the highest concentration in a single fortnight since January. The transactions aggregated $28.7 billion in disclosed value—though the real figure is likely substantially higher, as 76% of deals had undisclosed terms. For context, the average buyer faced a deal size of $1.3 billion.

The velocity is striking. On a single day this week (May 27), 26 acquisition announcements landed in the deal flow—a pace that typically signals either panic buying or genuine optionality in the market. The evidence points to the latter. Buyers are not desperate; they are patient capital moving when the fit is right.

Technology Deals Set the Pace

Technology acquisitions claimed 26 deals and $1.3 billion in disclosed value. That's 31% of all deal activity by count, though only 4.5% of disclosed capital. The discrepancy reveals the nature of tech M&A in this window: strategic roll-ups in staffing, consulting, data infrastructure, and talent platforms, where buyer rationale is anchored to revenue synergy and team retention, not headline valuations.

Consider the patterns. Bain-backed data center operator Hscale closed on a second facility outside Milan. Toptal expanded consulting capacity by acquiring Adeva. Exploring Technology bought a controlling stake in Yiwu Blanket King for $1.7 billion, signaling conviction that AI manufacturing upside remains undervalued in traditional hard-goods industries. Each transaction follows the same template: acquire capabilities, fold into an existing platform, extract margin. No mega-deals; all muscle-building.

Financial services and insurance firms deployed $6.2 billion in disclosed capital across just seven transactions. Bluespring Wealth's purchase of Synthesis Wealth Planning for $1.1 billion stands out as a wealth platform consolidation. Elsewhere, trading platforms and fintech payment specialists attracted smaller buyers, each deal in the $50–300 million range. The sector is consolidating at two speeds: mega-managers buying portfolio companies (which inflates per-deal averages), and smaller buyers picking off niche players in specialized niches.

Healthcare Roll-Ups Accelerate

Healthcare delivered five announced acquisitions with $336 million in disclosed terms. Olympus' $270 million purchase of BioProtect to expand urology and prostate cancer capabilities exemplifies the category. Maipu Medical acquired Yijie Medical for $335 million, and CordenPharma moved on AmbioPharm to scale peptide API production. These are not carve-outs or distressed sales; they are strategic expansions by well-capitalized buyers betting on specific disease areas or manufacturing scale.

The lesson: healthcare consolidation remains steady-state, neither accelerating nor decelerating. The sector's regulatory friction and clinical validation requirements keep deal sizes modest and buyer discipline tight. No surprises, but no stalls either.

Real Estate Bounces Back

Real estate investors announced four deals, anchored by Sixth Street's acquisition of Park Hyatt Beaver Creek Resort & Spa and Sagard Real Estate's 222-unit Seattle multifamily purchase. PGIM deployed $260 million in its 10th property acquisition under its recent fund close. The sector's reemergence in the deal flow—rare over the prior 60 days—suggests buyer confidence in long-term fundamentals. Hospitality and workforce housing are moving again.

Where the Largest Deals Sit

The single largest transaction in the window was undisclosed, but market intelligence points to cross-border infrastructure and energy plays. Jardine Matheson's $3.4 billion acquisition of I-MED Radiology in Australia and Northern Oil's $350 million play on Duvernay assets in Canada both sit in the AUD/CAD space—currency plays that buyers expect to hedge or monetize. These deals are not momentum; they are conviction bets on asset-class-specific returns.

The Unclassified $16.8 Billion

Thirty-seven deals landed in the "other" bucket, generating $16.8 billion in disclosed value. This category includes staffing acquisitions (CC Pace, Kleinschmidt purchases), food manufacturing (InfiniteRoots acquiring Bosque Foods to scale mycelium production), and a raft of mid-market bolt-ons where buyer and asset are too specific to generalize. The clustering here underscores a simple truth: most M&A activity happens at the margin, in deals under $500 million where strategic fit drives price, not market multiples.

Deal Size Concentration

Forty-five deals fell below $100 million—likely undisclosed or small platform acquisitions. Twenty-two ranged from $100–500 million. Twelve sit in the $500M–1B band. Five deals topped $1 billion. A single transaction exceeded $5 billion (undisclosed). The curve confirms the pattern: most M&A is small, tactical, and driven by operational need rather than return multiple expansion.

What This Momentum Signals

Deal velocity is not a reliable leading indicator of market direction. Macro uncertainty, rising rates, and FX volatility can persist alongside robust transaction flow. But sustained deal-making at this pace suggests:

• Capital is flowing toward operational payoff. Buyers are not speculating on exit multiples; they are buying to integrate, cut costs, or fold into existing platforms.
• Technology and financial services remain acquisition hot-spots. These sectors retain pricing power and can justify M&A on revenue synergy, not cost cuts.
• Real estate is thawing. A 60-day gap followed by four announced deals in one week suggests sentiment is shifting on property valuations.
• Geographic arbitrage persists. The uptick in AUD, CAD, and other currencies in the deal window points to buyers hedging via cross-border consolidation.

The Pipeline Ahead

If this pace holds—and historical data suggest it will fluctuate by 20–30% around a 70–90 deal-per-month baseline—Q2 will exceed $120 billion in announced M&A. That would mark a 15% increase over Q1 2026. For buyers, the takeaway is clear: patience is rewarded. Sellers, meanwhile, should expect higher competition for assets priced competitively on fundamentals, and softer bids for speculative plays.

The market is saying it values cash-generative assets and strategic fit over multiple arbitrage. That discipline may not last, but for now, deal-makers are executing on conviction rather than momentum.